Company MabVax Therapeutics Holdings, Inc.

Equities

MBVXQ

US55414P7024

Biotechnology & Medical Research

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for MabVax Therapeutics Holdings, Inc. +10.05% +182.21%

Business Summary

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Managers

Managers TitleAgeSince
Chief Executive Officer 72 -
Chief Tech/Sci/R&D Officer 81 14-07-07
Chief Tech/Sci/R&D Officer 68 14-07-07
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 81 14-07-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 33,333 0 0 92.02 %
Stock B 0 44,104 0 0
Stock C 1 9,429,582 8,677,104 ( 92.02 %) 0

Company contact information

MabVax Therapeutics Holdings, Inc.

559 Evans Mountain Road

72031, Clinton

+858-259-9405

address MabVax Therapeutics Holdings, Inc.(MBVXQ)
  1. Stock Market
  2. Equities
  3. MBVXQ Stock
  4. Company MabVax Therapeutics Holdings, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW